drugset
drugset / Trial / NCT04324814

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

NCT04324814 ↗

Phase 1 Completed 41 enrolled Atridia Pty Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.

Timeline

Start
2020-03-31
Primary completion
2023-02-01
Completion
2023-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Retlirafusp alfa Protein / enzyme biologic — —

Indications

neoplasm